49.51
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Precedente Chiudi:
$48.81
Aprire:
$47.1
Volume 24 ore:
1.72M
Relative Volume:
0.91
Capitalizzazione di mercato:
$4.75B
Reddito:
$3.51M
Utile/perdita netta:
$-581.60M
Rapporto P/E:
-7.60
EPS:
-6.5145
Flusso di cassa netto:
$-345.93M
1 W Prestazione:
+4.12%
1M Prestazione:
-18.53%
6M Prestazione:
-32.01%
1 anno Prestazione:
+44.81%
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Nome
Crispr Therapeutics Ag
Settore
Industria
Telefono
(617) 315-4600
Indirizzo
BAARERSTRASSE 14, ZUG
Compare CRSP vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
CRSP
Crispr Therapeutics Ag
|
49.51 | 4.75B | 3.51M | -581.60M | -345.93M | -6.5145 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-18 | Iniziato | JP Morgan | Overweight |
| 2025-02-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Aggiornamento | TD Cowen | Sell → Hold |
| 2025-02-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-06 | Reiterato | Needham | Buy |
| 2024-08-02 | Iniziato | Rodman & Renshaw | Buy |
| 2024-06-28 | Ripresa | Guggenheim | Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-11 | Downgrade | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Iniziato | Mizuho | Buy |
| 2023-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-04-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-03-17 | Iniziato | Bryan Garnier | Buy |
| 2023-03-07 | Iniziato | Robert W. Baird | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Underweight |
| 2022-08-09 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-04-21 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-10 | Reiterato | Chardan Capital Markets | Buy |
| 2020-12-10 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-10 | Reiterato | Needham | Buy |
| 2020-12-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Iniziato | BofA Securities | Buy |
| 2020-07-28 | Reiterato | Needham | Buy |
| 2020-07-14 | Iniziato | SunTrust | Buy |
| 2020-06-15 | Reiterato | Canaccord Genuity | Buy |
| 2020-03-05 | Iniziato | Stifel | Hold |
| 2020-02-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Iniziato | Jefferies | Buy |
| 2019-07-26 | Iniziato | Canaccord Genuity | Buy |
| 2019-06-10 | Iniziato | ROTH Capital | Buy |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-14 | Iniziato | William Blair | Mkt Perform |
| 2019-01-28 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-22 | Downgrade | Citigroup | Neutral → Sell |
Mostra tutto
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
CRISPR Therapeutics AG (CRSP) latest stock news and headlines - Yahoo Finance Australia
CRISPR Therapeutics AG (CRSP) Stock Price, News, Quote & History - Yahoo! Finance Canada
CRISPR Therapeutics AG (CRSP) stock price, news, quote and history - Yahoo Finance UK
Assessing CRISPR Therapeutics (CRSP) Valuation As Casgevy Revenue And Cash Position Support Its Growth Transition - sahmcapital.com
CRISPR Therapeutics Hits Day Low of $50.66 Amid Price Pressure - Markets Mojo
Did CRISPR’s Cash Raise, Casgevy Launch and Insider Buying Just Shift CRISPR Therapeutics' (CRSP) Investment Narrative? - Sahm
CRISPR Therapeutics AG (CRSP) rises higher than market: Key facts - MSN
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts - Yahoo Finance
CRISPR Therapeutics (NASDAQ: CRSP) asks shareholders to approve pay, capital and equity plan - Stock Titan
CRISPR Therapeutics AG (0VRQ.L) stock price, news, quote and history - Yahoo Finance UK
CRISPR Therapeutics AG (CRSP) exceeds market returns: Some facts to consider - MSN
CRISPR Therapeutics AG (CRSP) Outperforms the Market: Key Points to Note - Bitget
CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Earnings Beat: Is CRISPR Therapeutics AG backed by strong institutional buying2026 Institutional Moves & Low Risk Entry Point Tips - baoquankhu1.vn
A Turning Point For Crispr Therapeutics As Commercial Growth Accelerates (NASDAQ:CRSP) - seekingalpha.com
Bond Watch: Is CRISPR Therapeutics AG backed by strong institutional buying2026 Chart Watch & Weekly High Return Stock Opportunities - baoquankhu1.vn
Mizuho Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP) - The Globe and Mail
I Expect Crispr Therapeutics To Break Out As 2026 Revenue Exceeds Expectations (CRSP) - seekingalpha.com
CRISPR Therapeutics: The Fundamental Standard-Bearer in a Fractured Genomic Sector - Barchart
CRISPR (CRSP) Rated Overweight on Gene Editing Growth - Insider Monkey
CRISPR Therapeutics AG Experiences Revision in Stock Evaluation Amid Market Volatility - Markets Mojo
CRISPR Therapeutics shares drop after announcing convertible notes sale - MSN
Return on equity % of CRISPR Therapeutics AG Shs Thailand Depositary Receipts Repr 1 Sh – SET:CRSP03 - TradingView
(CRSP) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Is CRISPR Therapeutics (CRSP) Attractive After Recent Share Price Pullback? - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Why CRISPR Therapeutics AG (CRSP) outpaced the stock market today - MSN
Trend Report: What is the long term forecast for CRISPR Therapeutics AG stockTrade Entry Report & Accurate Intraday Trading Signals - baoquankhu1.vn
CRISPR Therapeutics stock faces uncertainty ahead of key earnings amid biotech sector volatility - AD HOC NEWS
Truist Financial Upgrades CRISPR Therapeutics (NASDAQ:CRSP) to "Strong-Buy" - marketbeat.com
CRISPR Therapeutics AG (CRSP) is a trending stock: Facts to know before betting on it - msn.com
Why CRISPR Therapeutics AG (CRSP) Performed Better Than the Market Today - Bitget
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today - Yahoo! Finance Canada
CRISPR Therapeutics stock dips on $350M convertible debt offering - MSN
CRISPR Therapeutics (NASDAQ:CRSP) General Counsel James Kasinger Sells 3,182 Shares - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells 10,020 Shares - MarketBeat
Crispr Therapeutics Insider Sold Shares Worth $468,736, According to a Recent SEC Filing - marketscreener.com
CRISPR (CRSP) GC granted options, RSUs; sells shares for taxes - stocktitan.net
CRISPR Therapeutics (CRSP) CEO gets major equity awards, sells shares for taxes - Stock Titan
[Form 4] CRISPR Therapeutics AG Insider Trading Activity - Stock Titan
CRISPR Therapeutics (NASDAQ: CRSP) grants CMO stock options and RSUs - Stock Titan
CRISPR Therapeutics Hits Day Low of $45.88 Amid Price Pressure - Markets Mojo
Crispr Therapeutics Ag Azioni (CRSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):